Artelo Biosciences, Inc. (NASDAQ: ARTL), the stock soared 92.31% to $2.02 in the pre-market session. The year-to-date performance of 42.47% was achieved by ARTL stock, with a performance of -8.77% over the last 7 days. Over the past month, the stock has gone up 48.81% while going up 108.21% over the past 3 months.
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company focused on developing proprietary therapeutics, including those targeting the endocannabinoid system.
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
- Stay-at-Home Stocks Still A Healthy Investment?
January 29, 2021, It was announced that Artelo Biosciences, Inc. (NASDAQ: ARTL) would have a virtual presentation at the LSX World Congress to be held February 1-5, 2021.
The presentation will be available on-demand until February 28, 2021. This webcast is available only to registered attendees. To register for the event while receiving complimentary viewing, please visit LSX World Congress.
It has been six years since the LSX World Congress has brought together the executives who are integral to the future of healthcare and life science strategy, investment, partnerships, and deal-making. In 2020, more than 1,000 executives attended the LSX World Congress in London, UK. For the LSX conference in 2021, the virtual conference will incorporate all the usual physical conference features. The industry’s top executives will attend the meeting, along with the field’s most active investors, BD&L teams in the pharmaceutical industry, and leading medical experts who are actively advancing healthcare and life sciences worldwide.
An analyst’s rating and target price serve as a guide to how a stock’s price compares to its market value, as well as a predictor of its performance in the future. It is estimated by the market GURU’sthat the ARTL stock price will rise by 65.33%. This was accomplished after a high price target of $3.00 was set on the shares. Also, analysts expect traders to keep the minimum stock price in the range of $3.00.
Biotech stocks offer the possibility of huge returns during the “golden age” of biotechnology, some experts say, pointing to a decade of developing new and better drugs.